Is INFIQ or RYLD a better dividend investment in 2026?

INFIQ currently yields 2000000.00% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: INFIQ offers higher current income.

What is the dividend yield difference between INFIQ and RYLD?

INFIQ has a forward dividend yield of 2000000.00% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 1999987.86 percentage points.

Home › Compare › INFIQ vs RYLD

INFIQ vs RYLD: Dividend Comparison 2026

INFIQ yields 2000000.00% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 INFIQ wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

INFIQ

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full INFIQ calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — INFIQ vs RYLD

📍 INFIQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	INFIQ	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, INFIQ + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

INFIQ pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INFIQ

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, INFIQ beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INFIQ + RYLD for your $10,000?

INFIQ: 50%RYLD: 50%

100% RYLD50/50100% INFIQ

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on INFIQ right now

INFIQ

Analyst Ratings

Buy

Hold

Consensus: Hold

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INFIQ buys

RYLD buys

No recent congressional trades found for INFIQ or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricINFIQRYLD

Forward yield	2000000.00% ✓	12.14%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.879226400974806e+39M	$44.5K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$2,587.35
Total dividends collected	$4.879195005460081e+39M	$18.8K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: INFIQ vs RYLD ($10,000, DRIP)

Year	INFIQ Portfolio	INFIQ Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,914	$1,213.65	+$200.00M → INFIQ
2	$3,738,731,768,458	$3,738,517,757,009.35	$14,099	$1,351.30	+$3738731.75M → INFIQ
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$16,580	$1,494.55	+$65315062866.91M → INFIQ
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$19,384	$1,642.61	+$1066400830062625.00M → INFIQ
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$22,535	$1,794.70	+$16272182796453826560.00M → INFIQ
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$26,063	$1,950.00	+$2.3205424011366188e+23M → INFIQ
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$29,995	$2,107.69	+$3.0927990661046884e+27M → INFIQ
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$34,361	$2,266.99	+$3.8524105697352695e+31M → INFIQ
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$39,194	$2,427.12	+$4.484688260147987e+35M → INFIQ
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$44,525	$2,587.35	+$4.879226400974806e+39M → INFIQ

INFIQ vs RYLD: Complete Analysis 2026

INFIQ — Stock

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024.

Full INFIQ Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this INFIQ vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INFIQ vs SCHD INFIQ vs JEPI INFIQ vs O INFIQ vs KO INFIQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.